. 2013 saw the successful integration of the Adis portfolio of journals into the Springer production systems and custombuilt platforms (SpringerLink, Springer for R&D, and Springer for Hospitals & Health). We are confident that our authors and subscribers benefit from improved discoverability, mobile optimisation and robust delivery of content on these platforms; and Springer production capacity has allowed us to increase the number of articles published whilst considerably reducing submission-to-publication times.
Looking ahead to 2014, the Adis portfolio will continue to grow the amount of content published while maintaining high standards. The number of Adis titles will also increase as existing quality Springer journals are brought under the Adis brand-Advances in Therapy, Targeted Oncology, and the European Journal of Drug Metabolism and Pharmacokinetics. Adis are also committed to fostering Open Access publication: all Adis titles offer the Springer Open Choice option and we are adding a further ten fully Open Access titles in specific therapy areas such as Diabetes Therapy, Cardiology and Therapy and Dermatology and Therapy, previously published under the Springer Healthcare imprint. Information about the portfolio can be found on Springer.com/Adis.
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